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ABSTRACT
Objective We aimed to determine the association 
between physician adherence to prescribing guideline-
recommended medications during hospitalisation and 
6-month major adverse outcomes of patients with acute 
coronary syndrome in Vietnam.
Design Prospective cohort study.
Setting The study was carried out in two public hospitals 
in Vietnam between January and October 2015. Patients 
were followed for 6 months after discharge.
Participants Patients who survived during hospitalisation 
with a discharge diagnosis of acute coronary syndrome 
and who were eligible for receiving at least one of the four 
guideline-recommended medications.
Exposures Guideline adherence was defined as 
prescribing all guideline-recommended medications at 
both hospital admission and discharge for eligible patients. 
Medications were antiplatelet agents, beta-blockers, ACE 
inhibitors or angiotensin II receptor blockers and statins.
Main outcome measure Six-month major adverse 
outcomes were defined as all-cause mortality or hospital 
readmission due to cardiovascular causes occurring 
during 6 months after discharge. Cox regression models 
were used to estimate the association between guideline 
adherence and 6-month major adverse outcomes.
Results Overall, 512 patients were included. Of those, 
there were 242 patients (47.3%) in the guideline 
adherence group and 270 patients (52.3%) in the non-
adherence group. The rate of 6-month major adverse 
outcomes was 30.5%. A 29% reduction in major adverse 
outcomes at 6 months after discharge was found for 
patients of the guideline adherence group compared with 
the non-adherence group (adjusted HR, 0.71; 95% CI, 0.51 
to 0.98; p=0.039). Covariates significantly associated with 
the major adverse outcomes were percutaneous coronary 
intervention, prior heart failure and renal insufficiency.
Conclusions In-hospital guideline adherence was 
associated with a significant decrease in major adverse 
outcomes up to 6 months after discharge. It supports the 
need for improving adherence to guidelines in hospital 
practice in low-income and middle-income countries like 
Vietnam.
InTRODuCTIOn
Ischaemic heart diseases (IHDs) are the 
leading cause of death worldwide, accounting 
for 13.2% of all deaths globally.1 More than 
80% of those occur in low-income and 
middle-income countries.2 IHDs comprise a 
spectrum of diseases of the heart including 
stable angina and acute coronary syndrome 
(ACS) which is the dominant cause of IHD 
deaths.3 In Vietnam, ACS is also one of the 
leading causes of mortality.4 International 
guidelines recommend using a combination 
of an antiplatelet agent, a beta-blocker, an 
ACE inhibitor or an angiotensin II receptor 
blocker (ACEI/ARB) and a statin to treat 
eligible patients with ACS.5–8 The Vietnam 
National Heart Association (VNHA) guide-
lines9 are in line with the international 
guidelines.5–8
Adherence to guidelines remains subop-
timal in clinical practice,10–13 in particular, 
Strengths and limitations of this study
 ► This is the first prospective cohort study to evaluate 
the association between physician performance 
and patients’ adverse outcomes in Vietnam, a lower 
middle-income country in Asia.
 ► Estimation of the sample size was not possible 
because previous studies identifying the association 
between in-hospital guideline adherence and 
postdischarge major adverse outcomes in low-
income and middle-income countries like Vietnam 
were not available.
 ► Although we attempted to address the impact of 
in-hospital guideline adherence on postdischarge 
adverse outcomes by adjusting for potential factors, 
the possibility of confounding by unmeasured 
covariates remains.
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in low-income and middle-income countries.14–16 In 
fact, in-hospital guideline adherence for patients with 
ACS in Vietnam was suboptimal.17 Prescribing of guide-
line-recommended medications has been shown to 
reduce both in-hospital and postdischarge morbidity 
and mortality.18–22 The impact of guideline adherence on 
mortality of patients with ACS during hospitalisation has 
been determined previously.23 Less data are available on 
the association between in-hospital guideline adherence 
and postdischarge major adverse outcomes in patients 
with ACS, especially from low-income and middle-income 
countries like Vietnam.
Therefore, we aimed to determine the association 
between in-hospital guidelines adherence and 6-month 
postdischarge major adverse outcomes of patients with 
ACS in Vietnam.
METhODS
Setting and study population
We conducted a prospective cohort study of patients 
discharged with a diagnosis of ACS. Patients were followed 
for 6 months after discharge. We selected the two largest 
public hospitals (central and provincial level) in the 
centre of Can Tho City, Vietnam with facilities to treat 
ACS. Within the region, these two hospitals provide the 
highest level of care to patients with ACS. Percutaneous 
coronary intervention (PCI) could be performed in the 
central hospital only. Study hospital wards were cardiac 
wards, intensive care units and cardiac interventional 
unit.
All eligible patients admitted to the study wards 
between January and October 2015 were approached for 
participation. The follow-up period ended in April 2016. 
We included patients who survived during hospitalisation 
with one of the following discharge diagnoses according 
to the coding of the International Classification of 
Diseases, 10th revision: unstable angina (I20.0), acute 
myocardial infarction (I21) or subsequent myocardial 
infarction (I22).24 Patients had to be eligible for receiving 
at least one of the four guideline-recommended medi-
cations. For patients who were admitted several times 
during the study period, we only included the first admis-
sion. We excluded patients (1) who had been admitted 
to another hospital initially and were transferred to the 
study site consequently; (2) who did not fully complete 
treatment therapy (ie, transferred to another hospital for 
further treatment, discharged without permission of their 
physicians, or discharged without a prescription because 
of severe illness); (3) or with missing data of treatment at 
hospital admission or discharge in their medical records.
The study was approved by the institutional review 
boards of the Can Tho Central General Hospital and Can 
Tho General Hospital in Can Tho City, Vietnam. Verbal 
consent was obtained from all participants by one of the 
researchers responsible for data collection (DTTT, LMH 
and TNDT). The researchers explained the main objec-
tive of the study and outlined all procedures involved to 
the patients and relatives/carers (if present). They were 
emphasised that participation did not affect their care, 
was voluntary and they could withdraw at any point in the 
study. This procedure was approved by the institutional 
review boards and is in line with Vietnamese regulations.
Data sources and data
Three researchers (DTTT, LMH and TNDT) collected 
data from medical records and patient interviews. 
Patients’ medical records were requested from the 
medical record archives of the two study hospitals 
using a predefined data collection form. Baseline data 
included demographic characteristics, coronary artery 
disease (CAD) risk factors, medical history and comor-
bidities, discharge diagnoses, hospital findings and 
undergoing PCI during hospitalisation. Hospital find-
ings comprised Killip class, estimated glomerular filtra-
tion rate (eGFR), heart rate, systolic blood pressure 
(SBP), left ventricular ejection fraction (LVEF), atrial 
ventricular (AV) block, aspartate aminotransferase or 
alanine aminotransferase (AST/ALT) levels and in-hos-
pital bleeding. Details of all medications prescribed 
within the first 24 hours after hospital admission and at 
hospital discharge were collected. Information on the 
contraindications to antiplatelet agents, beta-blockers, 
ACEIs/ARBs or statins was also recorded. Researchers 
asked physicians if baseline data were missing in the 
medical records.
During the follow-up period, patients, their relatives 
or both were interviewed twice to collect information on 
major adverse outcomes. The first interview took place on 
day 31 (or within 2 weeks) after discharge and the second 
on day 181 (or within 2 weeks) after discharge. The end of 
the follow-up period was either the date of 6 months after 
discharge or the date of death, whichever occurred first.
Guideline adherence
Guideline adherence was defined as prescribing all 
guideline-recommended medications at both hospital 
admission and discharge for patients eligible to receive 
the medications. Guidelines used in the study were the 
current version of the VNHA,9 the European Society of 
Cardiology7 8 and the American College of Cardiology/
American Heart Association.5 6 All three guidelines 
recommend the use of an antiplatelet agent (aspirin, 
clopidogrel or both), a beta-blocker, an ACEI/ARB and 
a statin within the first 24 hours after hospital admission 
and at hospital discharge. We have described the criteria 
to be eligible for being prescribed the medications else-
where.17 Briefly, patients eligible for being prescribed 
an antiplatelet agent, a beta-blocker or a statin were all 
patients who did not have contraindications to the medi-
cations. Patients eligible for being prescribed an ACEI/
ARB were patients with prior heart failure, an LVEF<40%, 
diabetes mellitus or hypertension, and no contraindica-
tions to the medication. Patients were stratified into two 
groups, exposed and unexposed to guideline adher-
ence. Hereafter, the exposed group was called ‘guideline 
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adherence group’, and the unexposed group was called 
‘guideline non-adherence group’.
Outcomes
Six-month major adverse outcomes were defined as 
all-cause mortality or hospital readmission due to cardio-
vascular causes (including ACS, stroke or any related 
cardiovascular diseases) occurring during 6 months after 
discharge.
Covariates
Covariates were identified because they are associated 
with risk of major adverse outcomes or with the like-
lihood of guideline adherence. The covariates might 
confound the association between guideline adherence 
and major adverse outcomes. The covariates associ-
ated with major adverse outcomes were based on rele-
vant studies. They were age,25 26 gender,27 28 discharge 
diagnosis (non-ST-elevation acute coronary syndrome 
(NSTEACS) or ST-elevation acute coronary syndrome 
(STEACS)),29 30 prior myocardial infarction/stroke,31 32 
prior heart failure,33–36 renal insufficiency (eGFR <60 or 
≥60 mL/min/1.73 m2),35–37 the number of CAD risk factors 
(including CAD family history, hypertension, diabetes, 
dyslipidemia and smoking),37 Killip class (I or ≥II),38 39 
SBP (<100 or ≥100 mm Hg),40 LVEF (<40% or ≥40%)41 
and PCI (undergoing or not).42–46 The covariates associ-
ated with the likelihood of guideline adherence were iden-
tified based on the differences in characteristics between 
guideline adherence and non-adherence groups. The 
cut-offs of continuous covariates were based on clinical 
relevance.5–9 17
Statistical methods
Data were presented as absolute numbers, percentages, 
means with SDs or medians with IQRs as appropriate. 
The frequencies of categorical variables of two patient 
groups were compared using the χ2 test or Fisher’s exact 
test. Continuous variables were compared using Student's 
t-test or Mann-Whitney test. A univariable Cox regression 
model was used to estimate the unadjusted HR with 95% 
CI of the association between in-hospital guideline adher-
ence and 6-month major adverse outcomes, and to explore 
the nature of the association based on type and number 
of guideline-recommended medications. Multivariable 
backward stepwise Cox regression models were used to 
estimate the association. The first model was adjusted 
for the covariates and the second model was adjusted for 
significant associated factors of the first model and inter-
action terms between these factors and guideline adher-
ence. Also Kaplan-Meier curves of surviving and not being 
readmitted due to cardiovascular causes were generated. 
In addition, we explored the impact of attrition bias due 
to dropouts in sensitivity analyses using multiple impu-
tations to impute missing outcomes and repeating the 
analyses on the basis of an imputed sample of all patients 
included at baseline. We also performed sensitivity anal-
yses excluding potential covariates affecting the major 
adverse outcomes. Furthermore, we performed subgroup 
analyses based on dropout status in order to compare 
the differences in baseline and treatment characteristics 
which could bias the association. All tests were two-sided. 
p Values of 0.05 or less were considered statistically 
significant. Analyses were performed using the Statistical 
Package for the Social Sciences, V24 (SPSS 24).
RESulTS
Of 706 hospital admissions due to ACS at baseline, 610 
(86.4%) patients were included; and 96 hospital admis-
sions (13.6%) were excluded due to the following 
reasons: in-hospital death (1 case), severely ill without a 
discharge prescription (21), transfer to another hospital 
(44), second admission (29) and patient record not being 
available (1). There were 328 included patients (53.8%) 
in the guideline non-adherence group and 282 included 
patients (46.2%) in the adherence group. There were 58 
dropouts (17.7%) in the non-adherence and 40 dropouts 
(14.2%) in the adherence group. In total, 512 patients 
completed the follow-up and were included in our anal-
ysis. Reasons for the dropouts were not available because 
we could not contact patients or their relatives (figure 1).
The median age (IQR) was 68 years (59 to 79), 54.7% 
were males and 79.7% had social health insurance. The 
majority of patients had hypertension (80.3%) and a 
discharge diagnosis of NSTEACS (68.6%), and did not 
undergo PCI (75.0%). Documented contraindications 
were in-hospital gastrointestinal bleeding (for anti-
platelet agents); asthma/chronic obstructive pulmonary 
disease (COPD), Killips class II–IV, heart rate<60 beats/
min, SBP<100 mm Hg, LVEF<40% and AV block II–III 
(beta-blockers); SBP<100 mm Hg and eGFR<30 mL/
min/1.73 m2 (ACEIs/ARBs); an increase of AST/ALT 
greater than three times the upper limit of normal 
(statins). There was a significant difference between the 
two groups in several characteristics: social health insur-
ance, Killip class II–IV, SBP<100 mm Hg and LVEF<40% 
(table 1).
There was guideline adherence in 242 patients (47.3%) 
and non-adherence in 270 patients (52.7%). The rate of 
6-month major adverse outcomes, mortality and hospital 
readmission were 30.5%, 12.0% and 23.6%, respectively. 
Six-month major adverse outcomes were significantly 
lower (p=0.014) in the guideline adherence group 
(25.2%) compared with those in the non-adherence 
group (35.2%). Mortality (10.6% vs 13.1%) and hospital 
readmission (19.8% vs 27.0%) were not statistically signif-
icant between the adherence and the non-adherence 
group.
Patients in the guideline adherence group had a lower 
risk of major adverse outcomes in univariable analysis 
(unadjusted HR=0.69; 95% CI 0.50 to 0.95; p=0.021) 
(table 2) and in multivariable analysis (adjusted HR=0.71; 
95% CI 0.51 to 0.98; p=0.039) after adjusting for PCI, 
prior heart failure and renal insufficiency (table 3 and 
figure 2). Patients had a lower risk of major adverse 
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outcomes when they received beta-blockers (unadjusted 
HR=0.46; 95% CI 0.29 to 0.72; p=0.001), or all four 
medications (unadjusted HR=0.37; 95% CI 0.20 to 0.66; 
p=0.001). 31.7% of patients received all four medications 
according to the guidelines (table 2). Patients undergoing 
PCI had a lower risk of major adverse outcomes (adjusted 
HR=0.60; 95% CI 0.38 to 0.95; p=0.024). Patients had a 
higher risk of major adverse outcomes when they had 
prior heart failure (adjusted HR=1.92; 95% CI 1.36 to 
2.69; p<0.001) or renal insufficiency (adjusted HR=1.38; 
95% CI 1.00 to 1.91; p=0.050) (table 3).
Subgroup analyses revealed that patients completing 
the follow-up compared with those dropping out were 
less likely to smoke and to receive antiplatelet agents, 
statins, at least two guideline-recommended medica-
tions (online supplementary appendix 1). In sensitivity 
analyses, patients in the guideline adherence group had 
a lower risk of major adverse outcomes after imputing 
dropouts’ censoring time and event occurrence (pooled 
HR=0.66; 95% CI 0.48 to 0.92; p=0.015), or excluding 
patients who underwent PCI (HR=0.70; 95% CI 0.49 to 
0.99; p=0.046), who had prior heart failure (HR=0.56; 
95% CI 0.36 to 0.89; p=0.013) or who had renal insuffi-




About half of patients were prescribed all medications 
according to guidelines. In about one-third of patients, 
a major adverse outcome occurred within 6 month of 
discharge. We found a 29% reduction in major adverse 
outcomes at 6 months after discharge for patients 
who received medications according to guidelines 
compared with those who did not. Prior heart failure, 
renal insufficiency or not receiving PCI also significantly 
increased the risk of major adverse outcomes.
Strengths and weaknesses of the study
As far as we are aware, no work has been done to eval-
uate the benefits of guideline adherence in treatment 
for patients with ACS in Vietnam or similar low-income 
and middle-income countries. The major strengths are 
the prospective cohort design to evaluate the association 
between physician performance and patients’ adverse 
outcomes in Vietnam, a middle-income Asian country. 
Both unadjusted and adjusted HRs showed similar bene-
fits of in-hospital guideline adherence. However, our 
study was conducted in two hospitals in one of 63 cities in 
Vietnam4; this potentially limited the generalisability of 
our findings. Nevertheless, our study included hospitals 
with and without onsite invasive procedures and prospec-
tively followed patients for 6 months.
Several issues in our study should be considered. First, 
we only had information on therapies during the index 
hospitalisation and did not have data on the use of 
guideline-recommended medications during follow-up, 
nor did we have data postdischarge on follow-up visits, 
side effects and the duration of the medical therapy, 
patients’ adherence to treatment and lifestyle modifica-
tion. All of these might influence postdischarge adverse 
outcomes. Second, although our study included patients 
without contraindications to guideline-recommended 
medications, physicians may have had concerns about 
adverse effects of these medications in some cases. For 
example, it has been shown that physicians were very 
cautious about prescribing a beta-blocker at discharge 
for older patients with ACS and diabetes,47 48 especially 
to patients living alone, not having an informal care 
provider. Differences between hospitals and physicians 
in the quality of care other than prescribing according 
Figure 1 Flowchart of study population
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to guidelines might also influence our findings. Further 
studies in a larger number of hospitals should consider 
the effect of covariates related to hospital and physician 
characteristics on the association between guideline 
adherence and patients' major adverse outcomes. 
Third, we only had information on all-cause mortality 
and the reason of readmission based on patient inter-
views. Cause-specific mortality/readmission was not 







  Age, median (IQR) years 68 (59; 79) 70 (59; 80) 66 (59; 79) 0.160†
  Age≥65, n (%) 298 (58.2) 166 (61.5) 132 (54.5) 0.112
  Male, n (%) 280 (54.7) 139 (51.5) 141 (58.3) 0.124
  Health insurance, n (%) 408 (79.7) 229 (84.8) 179 (74.0) 0.002
  Hospital length of stay, median (IQR) days 9 (7; 12) 9 (7; 12) 9 (7; 12) 0.811†
CAD risk factors
  CAD family history, n (%) 29 (5.7) 17 (6.3) 12 (5.0) 0.513
  Hypertension, n (%) 411 (80.3) 220 (81.5) 191 (78.9) 0.468
  Diabetes, n (%) 119 (23.2) 66 (24.4) 53 (21.9) 0.496
  Dyslipidemia, n (%) 127 (24.8) 68 (25.5) 59 (24.4) 0.833
  Smoking, n (%) 196 (38.3) 100 (37.0) 96 (39.7) 0.541
  Number of CAD risk factors, median (IQR) 2 (1; 2) 2 (1; 2) 2 (1;2) 0.643†
Medical history and comorbidities, n (%)
  Prior MI/stroke 150 (29.3) 76 (28.1) 74 (30.6) 0.546
  Prior PCI/CABG 19 (3.7) 9 (3.3) 10 (4.1) 0.633
  Prior heart failure 137 (25.8) 70 (25.9) 62 (25.6) 0.937
  Peptic ulcer 197 (38.5) 112 (41.5) 85 (35.1) 0.140
  Asthma/COPD 22 (4.3) 13 (4.8) 9 (3.7) 0.542
Hospital findings, n (%)
  Killip class II–IV 61 (11.9) 11 (4.1) 50 (20.7) <0.001
  eGFR<60 mL/min/1.73 m2 223 (43.6) 111 (41.1) 112 (46.3) 0.239
  eGFR<30 mL/min/1.73 m2 29 (5.7) 15 (5.6) 14 (5.8) 0.911
  Heart rate<60 beats/min 30 (5.9) 12 (4.4) 18 (7.4) 0.150
  SBP<100 mm Hg 56 (10.9) 11 (4.1) 45 (18.6) <0.001
  LVEF<40% 57 (11.1) 10 (3.7) 47 (19.4) <0.001
  AV block II–III 7 (1.4) 5 (1.9) 2 (0.8) 0.455‡
  AST/ALT increased 84 (16.4) 43 (15.9) 41 (16.9) 0.757
  In-hospital GI bleeding 11 (2.1) 7 (2.6) 4 (1.7) 0.464
Discharge diagnosis, n (%)
  NSTEACS 351 (68.6) 186 (68.9) 165 (68.2) 0.863
  STEACS 161 (31.4) 84 (31.1) 77 (31.98)
In-hospital revascularisation procedures, n (%)
  No PCI 384 (75.0) 218 (80.7) 166 (68.6) 0.002
  PCI 128 (25.0) 52 (19.3) 76 (31.4)
*Using the χ2 test if other tests were not mentioned.
†Using Mann-Whitney test.
‡Using Fisher's exact test.
ACS, acute coronary syndrome; AST/ALT, aspartate aminotransferase or alanine aminotransferase; AV, atrial ventricular; CABG, coronary 
artery bypass grafting; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; LVEF, left ventricular 
ejection fraction; MI, myocardial infarction; NSTACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; 
SBP, systolic blood pressure; STEACS, ST-elevation acute coronary syndrome.
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possible to assess in our study as patients were read-
mitted to different hospitals. It was outside the scope of 
our study to collect data from these hospitals. Fourth, 
although we attempted to address postdischarge 
adverse outcomes by adjusting for potential factors, 
the possibility of confounding by unmeasured covari-
ates such as other comorbidities or ECG characteristics 
remains. Fifth, estimation of the sample size was not 
possible because previous studies identifying the asso-
ciation between in-hospital guideline adherence and 
postdischarge major adverse outcomes in low-income 



















































































































































































































































































































































































































































































































































































































Table 3 Factor associated with 6-month major adverse 
outcomes
Factor HR* 95% CI p Value
In-hospital guideline 
adherence
0.71 0.51 to 0.98 0.039
Percutaneous coronary 
intervention
0.60 0.38 to 0.94 0.024
Prior heart failure 1.92 1.36 to 2.69 <0.001
Renal insufficiency 1.38 1.00 to 1.91 0.050
*Using multivariable backward stepwise Cox regression models. 
First model: variables entered at the first step: age, gender, 
number of CAD risk factors, prior MI/stroke, prior heart failure, 
Killip class II–IV, renal insufficiency, SBP<100 mm Hg, LVEF<40%, 
in-hospital guideline adherence, discharge diagnosis, PCI and 
health insurance. Second model: variables entered at the first 
step: in-hospital guideline adherence, percutaneous coronary 
intervention, prior heart failure, renal insufficiency and interaction 
terms: in-hospital guideline adherence and percutaneous coronary 
intervention, in-hospital guideline adherence and prior heart failure, 
in-hospital guideline adherence and renal insufficiency.
CAD, coronary artery disease; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; PCI, percutaneous coronary 
intervention; SBP, systolic blood pressure.
Figure 2 Kaplan-Meier curves for two groups associated 
with major adverse outcomes
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available. Sixth, we excluded a substantial proportion 
of patients at baseline because of predefined exclusion 
criteria. The quality of treatment for these patients, 
especially for patients who were severely ill or who were 
transferred to another hospital, could be addressed in 
future studies. Finally, there was a substantial propor-
tion of dropouts during follow-up. Although baseline 
characteristics and the proportion of patients receiving 
in-hospital guideline adherence between dropouts and 
patients completing the study were similar, there were 
several considerable differences. However, the results of 
sensitivity analyses all confirmed the significant impact 
of in-hospital guideline adherence on 6-month major 
adverse outcomes.
Possible explanations and comparison with other studies
Physician adherence to prescribing guideline-recom-
mended medications in Vietnam was suboptimal, lower 
than other countries' figures with more than two-third 
being adherent to guidelines.49–51 This could explain 
the high rate of 6-month major adverse outcomes of 
patients with ACS in Vietnam (about one-third) which 
was higher than the figures in other countries.52 53 The 
impact of in-hospital guideline adherence on improved 
6-month major adverse outcomes could be the result 
of several mechanisms. First, appropriately prescribing 
guideline-recommended medications may result in 
less myocardial damage, which improves postdischarge 
outcomes among those surviving to hospital discharge.5–9 
Our findings also showed that patients without major 
adverse outcomes were more likely to receive beta-
blockers (vs not receive), or all four guideline-rec-
ommended medications (vs <4 medications) during 
hospitalisation. However, less than one-third of eligible 
patients received all four medications according to the 
guidelines in our study which was lower than in other 
studies.46 54 55 Further studies could investigate associated 
factors and benefits of receiving all four medications or 
beta-blockers in our patient group in Vietnam. Also, the 
application of PCI may have an impact on the medica-
tions prescribed according to guidelines; both strategies 
were known to reduce mortality.42 49 51 The initiation of 
PCI and the medications at the index hospitalisation 
are also a predictor of their consistent use during the 
follow-up period, an important contributor to the reduc-
tion of postdischarge adverse outcomes.42 43 The risk 
reduction persists to 6 months after discharge, suggesting 
that prescribing guideline-recommended medications 
at the index hospitalisation continues to modulate 
outcomes. Our findings are consistent with previous 
studies reporting that guideline adherence during hospi-
talisation was associated with a significant decrease in 
postdischarge adverse outcomes, ranging from 10% to 
55%.49 51 56 The results are difficult to compare due to 
considerable differences such as (1) measuring physician 
adherence at discharge44 46 50 56 or during hospitalisa-
tion45 49 51 57; (2) prescribing of individual medications45 
or different composites44 46 49–51 56 57; (3) measuring 
guideline adherence with45 56 57 or without44 46 49–51 
including invasive procedures; (4) measuring different 
adverse outcomes such as death,41 43–45 49 50 58 readmission 
to hospital,56 occurrence of major adverse events50 56 or 
their combination56; (5) different follow-up periods such 
as 6 months,44 56 1 year45 46 50 51 56 57 or longer49 51; and (6) 
the analyses adjusting for different covariates.
COnCluSIOnS AnD IMPlICATIOnS
We found that in-hospital guideline adherence was 
associated with a significant decrease in 6-month major 
adverse outcomes of patients with ACS in Vietnam. The 
data strongly support the need for continued efforts to 
improve adherence to guidelines and confirm the impor-
tance of evidence-based medicine in usual clinical care. 
These findings could also stimulate efforts to implement 
system strategies to reduce excess mortality and avoid-
able readmissions. It argues for further studies of the 
effectiveness of guideline adherence in other healthcare 
settings, especially in low-income and middle-income 
countries.
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